Available Only Through Your Veterinarian

ArthriEase-GOLD®

Powders, Soft Chews, and Tablets

Formulated to provide support for pets in need of advanced joint care. Great for senior pets, and those recovering from joint related injuries or surgery; or when the most support is needed.

+ Increases activity**
+ Clinically Tested!
+ Specifically formulated to support healthy hip & joint function
+ Assists in maintaining joint flexibility
+ Helps alleviate aches & discomfort associated with daily exercise
+ Helps support structural joint integrity and connective tissues

* Callender, K., Eli Data Consulting, LLC (2014) Efficacy and Safety of an Oral Nutraceutical in Dogs with Osteoarthritis: A Double Blind Placebo Controlled Study (Page 2 and 3).

** In a 70 dog study, dogs on ArthriEase-GOLD had 2.6 greater odds of showing an increase in activity after 25 days of treatment, compared to dogs on a placebo. Results may vary.

Common Areas of Joint Pain

- Shoulder Joint
- Elbow Joint
- Wrist Joint
- Hip Joint
- Knee Joint
- Hock Joint

Real Dogs, Real Results

A special thanks to all our furry friends who participated in our study.***

*** Just a precious few of the 70 dogs that participated.

ArthriEase-GOLD®

Hip & Joint Support

A Double-Blind Placebo-Controlled Joint Study

Products manufactured in Temecula, CA, USA
Federal Drug Administration (FDA) Audited
National Animal Supplement Council (NASC) Audited
Third Party Audited By U.L. Labs

GARMON CORP. / VETCLASSICS
27461 VIA INDUSTRIA, TEMECULA, CA 92590
888-628-8783 | WWW.VETCLASSICS.COM
The Efficacy and Safety of an Oral Nutraceutical on Dogs with Osteoarthritis: A Double-Blind Placebo-Controlled Study conducted at the University of Minnesota

Objective:
To assess the safety and efficacy of an oral supplement for the treatment of pain and decreased mobility in dogs with osteoarthritis in one or more joints.

Methods:
This was a randomized, double-blind, placebo-controlled in vivo clinical trial that was conducted on 70 otherwise healthy dogs with clinical osteoarthritic symptoms at the University of Minnesota, St. Paul, MN. The environment was positive controlled, simulating realistic use of the supplement.

Study Measurements:
After enrollment, each dog was fitted with an accelerometer collar which monitored activity level, giving real-time, total activity, and intensity level updates every 60-seconds for the duration of the 49 day study period. The accelerometers were used previously validated for the use of monitoring activity in dogs with arthritis.

In addition, owners completed a validated osteoarthritis questionnaire (Canine Brief Pain Inventory) before enrollment and at each re-examination where they reported the pain of their dogs on a scale from 0 to 10, with 10 indicating most severe pain and 0 indicating no pain at all. Owners separately reported the worst pain, least pain, average pain, and current pain of their dogs at four different time points (see graph on opposite page). After 7 days of monitoring normal patient activity each patient was randomized to the treatment or placebo group. Patient exams and owner questionnaires were completed on day 0, 7, 28, and 49 of the study.

Results:
Dogs were evaluated as individuals for the analysis of the data. Activity for the first seven days was averaged to establish a baseline for each individual dog’s level of activity. It was observed that dogs in the treatment group had significantly more activity during the study period compared to the placebo group.

Clinically Tested ArthriEase-GOLD was formulated by veterinarian Dr. Pedro Rivera, founder of the Oasis Wellness Center in Wisconsin. ArthriEase-GOLD contains the highest quality active ingredients to help maintain joint flexibility which may help to alleviate aches and discomfort associated with daily exercise or activity.

<table>
<thead>
<tr>
<th>Clinical Study Pain Measurement</th>
<th>Average Pain of Dogs*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>4.0</td>
</tr>
<tr>
<td>ArthriEase-GOLD</td>
<td>3.5</td>
</tr>
<tr>
<td>Day 0</td>
<td>3.0</td>
</tr>
<tr>
<td>Day 28</td>
<td>2.5</td>
</tr>
<tr>
<td>Day 49</td>
<td>2.0</td>
</tr>
</tbody>
</table>

1. Dogs on ArthriEase-GOLD had 2.6 greater odds of showing an increase in activity after 25 days of treatment, compared to dogs on a placebo.* Results may vary.
2. Dogs on ArthriEase-GOLD showed a trending decrease in owner-reported average pain compared to dogs on the placebo 28 days following the baseline period.* Similar patterns were found for owner-reported current level of their dog’s pain, lowest level of their dog’s pain, and worst level of their dog’s pain. On day 49, the average pain for the dogs on ArthriEase-GOLD was over 30% less compared to the dogs on the placebo.*
3. There were no adverse events or product related safety concerns during the 70 day study. Over one million doses have been administered since 1994 with no significant adverse events related to this product.

For more product information, frequently asked questions, and special offers, visit www.VETCLASSICS.com